<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="22014">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02820259</url>
  </required_header>
  <id_info>
    <org_study_id>35RC16_9755</org_study_id>
    <nct_id>NCT02820259</nct_id>
  </id_info>
  <brief_title>Therapeutic Drug Monitoring of Tacrolimus Biliary Concentrations for Liver-transplanted Patients (STABILE)</brief_title>
  <acronym>STABILE</acronym>
  <official_title>Therapeutic Drug Monitoring of Tacrolimus Biliary Concentrations for Liver-transplanted Patients (STABILE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that the biliary concentration of TCR is a good
      marker of its immunosuppressive activity.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>coefficient of correlation (rÂ²) between the biliary concentration of TCR and concentration within PBMC</measure>
    <time_frame>during the first 7 days after its initiation</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Biliary Concentration of Tacrolimus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        liver-transplanted patients who receive tacrolimus
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (&gt; 18 years) of both sexes,

          -  Candidates for liver transplantation or retransplantation, whatever the etiology and
             severity of the underlying disease,

          -  Not having expressed their opposition to participation in the study

        Exclusion Criteria:

          -  Bilio-enteric anastomosis,

          -  Associated transplantation of another organ

          -  Contraindications to TCR administration

          -  Delayed introduction of TCR (beyond the 5th postoperative day) whatever the cause.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michel MR RAYAR, MD</last_name>
    <phone>299288498</phone>
    <phone_ext>+33</phone_ext>
    <email>michel.rayar@chu-rennes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristell KC COAT</last_name>
    <phone>299289191</phone>
    <phone_ext>+33</phone_ext>
    <email>kristell.coat@chu-rennes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre hospitalier universitaire de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>michel MR Rayar, MD</last_name>
      <phone>299288498</phone>
      <phone_ext>33</phone_ext>
      <email>michel.rayar@chu-rennes.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>July 19, 2016</lastchanged_date>
  <firstreceived_date>June 24, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
